NPS Pharmaceuticals, Inc. (NPSP) New Findings from Replace Study Support Potential of Natpara(TM) to Treat Adult Hypoparathyroidism
6/25/2012 10:33:54 AM
TER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today that new findings from the double-blind, placebo-controlled Phase 3 REPLACE study of Natpara™ (recombinant human parathyroid hormone (rhPTH [1-84])) support the drug’s therapeutic potential as the first parathyroid hormone replacement therapy for adults with hypoparathyroidism. The findings were presented in oral and poster sessions at the ENDO 2012 annual meeting of The Endocrine Society in Houston, TX. Natpara is a bioengineered replica of human parathyroid hormone that is being developed by NPS Pharmaceuticals as the first replacement therapy for adults with hypoparathyroidism.
comments powered by